Jiangsu GDK Biotechnology Co Ltd - Asset Resilience Ratio
Jiangsu GDK Biotechnology Co Ltd (688670) has an Asset Resilience Ratio of 5.97% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688670 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Jiangsu GDK Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Jiangsu GDK Biotechnology Co Ltd (688670) total assets.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu GDK Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688670 current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥81.01 Million | 5.97% |
| Total Liquid Assets | CN¥81.01 Million | 5.97% |
Asset Resilience Insights
- Limited Liquidity: Jiangsu GDK Biotechnology Co Ltd maintains only 5.97% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu GDK Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu GDK Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Jiangsu GDK Biotechnology Co Ltd (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Jiangsu GDK Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.69% | CN¥109.05 Million ≈ $15.96 Million |
CN¥1.42 Billion ≈ $207.59 Million |
-5.06pp |
| 2024-12-31 | 12.75% | CN¥195.39 Million ≈ $28.59 Million |
CN¥1.53 Billion ≈ $224.31 Million |
+2.00pp |
| 2023-12-31 | 10.75% | CN¥175.42 Million ≈ $25.67 Million |
CN¥1.63 Billion ≈ $238.75 Million |
-10.63pp |
| 2022-12-31 | 21.38% | CN¥390.57 Million ≈ $57.15 Million |
CN¥1.83 Billion ≈ $267.31 Million |
-16.08pp |
| 2021-12-31 | 37.46% | CN¥657.31 Million ≈ $96.19 Million |
CN¥1.75 Billion ≈ $256.74 Million |
+32.32pp |
| 2020-12-31 | 5.14% | CN¥40.00 Million ≈ $5.85 Million |
CN¥777.98 Million ≈ $113.84 Million |
+2.84pp |
| 2019-12-31 | 2.30% | CN¥9.13 Million ≈ $1.34 Million |
CN¥397.30 Million ≈ $58.14 Million |
-- |
About Jiangsu GDK Biotechnology Co Ltd
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines. The company human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Jiangsu Gdk Biological Technology Co., Ltd was founded in 2008… Read more